Substantiation of the base composition with the purpose of creation of a soft dosage form for treating a wound process


  • V. V. Shmatenko Ukrainian Military Medical Academy, Ukraine



osmotic activity, base carrier, hydrophilic non-aqueous solvents, wound process, medicine, soft dosage form


During development of a semisolid medicinal product for the treatment of pyoinflammatory processes a special attention is paid to selection of an ointment base. The modern manufacturing of soft dosage forms for treating pyoinflammatory processes gives advantage to medicines on the hydrophilic base, which can be applied on a wound surface without disturbing perspiration. The absence of domestic medicines for treating a wound process when transferring from stage 1 to stage 2 makes particularly topical a research in developing new combined ointments for treating a wound process. One of the most important indicators of the specific action of a medicine for treating a wound process is the osmotic activity, which is involved in dehydration of a microbial cell and leads to a significant reduction of the biological activity and resistance of microbes. The osmotic activity of the samples of the ointment bases has been studied in vitro by the method of dialysis through a semi-permeable membrane in order to substantiate the optimal ointment base carrier and develop an ointment with the antibacterial and anti-inflammatory action. It has been experimentally found that the base containing the alloy of PEO-400 and PEO-1500 has the best dehydrating properties. When creating ointments for treating a wound process in transferring from stage 1 to stage 2 it should be taken into account that the most optimal are combined bases with a high effect of active medicinal substances release that intensifies their stimulating effect, as well as bases with the ability to create a moderate level of dehydration. Therefore, during the experiment in order to create a combined emulsion ointment base the following emulsifiers have been chosen – MSG and cetostearyl alcohol in the amount of 3% and 5%, respectively. Vaseline oil – 20% has been used as an oil phase (the aqueous phase is purified water – up to100 %). Based on the osmotic research conducted the composition of the emulsion base for the ointment has been substantiated; it contains: PEO-400 – 4%, PEO-1500 – 1%, MSG – 3%, cetostearyl alcohol – 5%, glycerol – 5%, vaseline oil – 20%, purified water – up to 100%.


Воловик Н.В., Ляпунов Н.А. // Фармаком. – 2001. – №2. – С. 1-10.

Гладух Є.В. // Вісник фармації. – 2002. – №4 (32). – С. 38-41.

Давтян Л.Л. // Фармац. журн. – 2003. – №3. – С. 74-77.

Допоміжні речовини та їх застосування в технології лікарських форм: довідковий посібник / Ф.Жогло, В.Возняк, В.Попович та ін. – Львів: Центр Європи, 1996. – 95 с.

Перцев И.М., Котенко А.М., Чуешов О.В., Халаева Е.Л. Фармацевтические и биологические аспекты мазей. – Х.: Изд-во НФаУ; Золотые страницы, 2003. – 288 с.

Сучасне медикаментозне лікування ран (Відомча інструкція). – К., 2002. − 35 с.

Chren M., Landefeld C.S. // JAMA. – 1994. – №22. – P. 1922-1925.

Gray J.E., McNamee P.M. // Sci. Rewiew Series. – 2000. – Vol. 1. – P. 38-49.

Maisch T. // Lasers in Medical Sci. – 2007. – Vol. 22, №2. – P. 83-91.

Young R., Lovell P. Introduction to Polymers. – London: Chapman&Hall, 1996. – 487 с.





Technology of Medicines